NCT07213830View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 10, 2025

Primary Completion Date

July 14, 2032

Study Completion Date

July 14, 2032

Conditions
Advanced Solid TumorMetastatic Solid Tumor
Interventions
BIOLOGICAL

IPN01203

Study intervention will be provided in a vial.

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT07213830 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies | Biotech Hunter | Biotech Hunter